NeuroScientific Biopharmaceuticals says its StemSmart stem cell therapy shows an 80% clinical response in a small group of five Crohn’s disease patients. According to the company’s update, four of the five treated patients respond, and all participants show clinical improvement. The reports also state that there are no serious adverse events associated with the treatment in this patient group.
The outlets present the same figures, framing the announcement as early-stage evidence based on the limited number of patients rather than a larger, controlled trial. The company’s results are described consistently as a short clinical response outcome, with improvement observed across the entire group and a response rate of 80%. Safety findings in the update are limited to the absence of serious adverse events in these five cases.
Overall, the coverage focuses on the company’s reported response and improvement rates for StemSmart in Crohn’s disease, alongside the stated safety outcome in the small cohort.
